Biocon Pharma receives ANDA approval for Mycophenolic acid
This further adds to Biocon’s portfolio of vertically integrated complex drug products
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The company has has 10 existing labs in India
The funds will be used to scale up existing operations and launch new products
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Owkin builds best-in-class predictive biomedical AI models and robust data sets
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Subscribe To Our Newsletter & Stay Updated